COMP <GO>
DXCM vs LLY // GROSS PROFIT MARGIN
DexCom Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: DXCM 4
— LLY 9
▲ GROSS PROFIT MARGIN LEADER: LLY
LAST: $82.29 (+2.95%) • MKT CAP: $30.16B
gross-margins
60.10%
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.29T
gross-margins
83.64%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DXCM VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | DXCM | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 60.10% | 83.64% | -23.54 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 21.60% | 32.36% | -10.76 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 25.2x | 36.4x | -11.22 | DXCM | /valuation <GO> |
| Free Cash Flow Yield | 3.57% | 2.30% | +1.27 | DXCM | /fcf-yield <GO> |
| Operating Margin | 19.60% | 40.21% | -20.61 | LLY | /operating-margins <GO> |
| Net Profit Margin | 17.90% | 31.90% | -14.00 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 15.60% | 45.51% | -29.91 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.14 | 9.29 | -2.15 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 9/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 41.8 | 66.6 | -24.80 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.10 | 0.51 | +0.59 | DXCM | /macro-sensitivity <GO> |
| Forward P/E Multiple | 30.3x | 30.6x | -0.32 | DXCM | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $30.16B | $1.29T | -$1.26T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | DXCM REV | LLY REV | DXCM GROSS % | LLY GROSS % | DXCM FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.66B | $65.18B | 60.1% | 83.0% | $1.08B | $16.81B |
| FY 2024 | $4.03B | $45.04B | 60.5% | 81.3% | $630.7M | $8.82B |
| FY 2023 | $3.62B | $34.12B | — | 79.3% | $585.5M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DXCM // BETA 1.10
LLY // BETA 0.51